234 related articles for article (PubMed ID: 7675648)
1. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
3. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
4. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
Meyer P; Bohnen NI; Barkan AL; Shapiro B
Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
7. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
9. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin-receptor scintigraphy of subcutaneous and thyroid metastases from bronchial carcinoid.
Krausz Y; Pfeffer MR; Glaser B; Lafair J
J Nucl Med; 1996 Sep; 37(9):1537-9. PubMed ID: 8790214
[TBL] [Abstract][Full Text] [Related]
11. The relevance of somatostatin receptors in thyroid neoplasia.
Ahlman H; Tisell LE; Wängberg B; Fjälling M; Forssell-Aronsson E; Kölby L; Nilsson O
Yale J Biol Med; 1997; 70(5-6):523-33. PubMed ID: 9825479
[TBL] [Abstract][Full Text] [Related]
12. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
13. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
14. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
15. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
16. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy.
Becker W; Schrell U; Buchfelder M; Hensen J; Wendler J; Gramatzki M; Wolf F
Nuklearmedizin; 1995 Jun; 34(3):100-3. PubMed ID: 7630741
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.
Limouris GS; Rassidakis A; Kondi-Paphiti A; Triantafyllou N; Manetou A; Giannakopoulos V; Toubanakis N; Psyhojios I; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1593-7. PubMed ID: 9179200
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
